Is MDGS or JNJ a better dividend investment in 2026?

MDGS currently yields 36.02% with a 5% 5-year dividend growth rate. JNJ yields 3.36% with 5.8% growth. The better choice depends on your goal: MDGS offers higher current income.

What is the dividend yield difference between MDGS and JNJ?

MDGS has a forward dividend yield of 36.02% ($0.85/share annually). JNJ yields 3.36% ($4.96/share annually). The yield gap is 32.66 percentage points.

Home › Compare › MDGS vs JNJ

MDGS vs JNJ: Dividend Comparison 2026

MDGS yields 36.02% · JNJ yields 3.36%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 MDGS wins by $166.2K in total portfolio value

INVESTMENT

TIME HORIZON10 years

MDGS

● Live price

36.02%

Share price

$2.36

Annual div

$0.85

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$186.2K

Annual income

$28,812.90

Full MDGS calculator →

JNJ

Johnson & Johnson

● Live price

3.36%

Share price

$147.50

Annual div

$4.96

5Y div CAGR

5.8%

Payout ratio

55%

After 10 yrs · $10,000 · DRIP

Portfolio value

$20.0K

Annual income

$827.78

Full JNJ calculator →

Portfolio growth — MDGS vs JNJ

📍 MDGS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	MDGS	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, MDGS + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

MDGS pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MDGS

Annual income on $10K today (after 15% tax)

$3,061.44/yr

After 10yr DRIP, annual income (after tax)

$24,490.97/yr

JNJ

Annual income on $10K today (after 15% tax)

$285.83/yr

After 10yr DRIP, annual income (after tax)

$703.61/yr

At 15% tax rate, MDGS beats the other by $23,787.35/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MDGS + JNJ for your $10,000?

MDGS: 50%JNJ: 50%

100% JNJ50/50100% MDGS

Portfolio after 10yr

$103.1K

Annual income

$14,820.34/yr

Blended yield

14.37%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

MDGS

No analyst data

Altman Z

3.0

Piotroski

4/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

+55.1% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MDGS buys

JNJ buys

No recent congressional trades found for MDGS or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricMDGSJNJ

Forward yield	36.02% ✓	3.36%
Annual dividend / share	$0.85	$4.96 ✓
Payout ratio	50% ✓	55%
1-year div growth	0%	4.2% ✓
5-year div CAGR	0%	5.8% ✓
Portfolio after 10y	$186.2K ✓	$20.0K
Annual income after 10y	$28,812.90 ✓	$827.78
Total dividends collected	$135.6K ✓	$5.6K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: MDGS vs JNJ ($10,000, DRIP)

Year	MDGS Portfolio	MDGS Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$14,302	$3,601.69	$10,676	$355.77	+$3.6K → MDGS
2	$20,117	$4,814.05	$11,407	$389.39	+$8.7K → MDGS
3	$27,854	$6,328.48	$12,198	$426.53	+$15.7K → MDGS
4	$37,992	$8,189.09	$13,056	$467.62	+$24.9K → MDGS
5	$51,091	$10,439.22	$13,987	$513.12	+$37.1K → MDGS
6	$67,787	$13,119.97	$14,998	$563.56	+$52.8K → MDGS
7	$88,801	$16,268.72	$16,098	$619.52	+$72.7K → MDGS
8	$114,935	$19,917.71	$17,295	$681.69	+$97.6K → MDGS
9	$147,073	$24,092.90	$18,599	$750.82	+$128.5K → MDGS
10	$186,181	$28,812.90	$20,022	$827.78	+$166.2K → MDGS

MDGS vs JNJ: Complete Analysis 2026

MDGS — Stock

Xylo Technologies Ltd, a technology-based company, provides medical-related devices and products in the United States, Europe, Asia, Israel, and internationally. The company operates through Corporate, E-commerce, Online Advertising & Internet Traffic Routing, Online Event Management, and Others segments. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it provides digital advertising platform; and operates online stores for the sale of various consumer products on the Amazon online marketplace, as well as an online event management and ticketing platform. Further, the company develops wireless vehicle battery charging technologies and modular electronic vehicles. The company was formerly known as Medigus Ltd. and changed its name to Xylo Technologies Ltd in April 2024. Xylo Technologies Ltd was incorporated in 1999 and is headquartered in Tel Aviv-Yafo, Israel.

Full MDGS Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →

📬

Get this MDGS vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MDGS vs SCHD MDGS vs JEPI MDGS vs O MDGS vs KO MDGS vs MAIN MDGS vs ABBV MDGS vs MRK MDGS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.